Ovarian Cancer Recurrent
Conditions
Brief summary
The goal of this clinical trial is to learn if drug regimen pegylated liposomal doxorubicin and adebrelimab with or without mirabegron works to treat relapsed ovarian cancer in adults. It will also learn about the safety of drug regimen pegylated liposomal doxorubicin and adebrelimab with or without mirabegron. The main questions it aims to answer are: Does drug pegylated liposomal doxorubicin and adebrelimab with or without mirabegron reduce tumor volume? What medical problems do participants have when taking drug pegylated liposomal doxorubicin and adebrelimab with or without mirabegron? Researchers will compare drug regimen pegylated liposomal doxorubicin and adebrelimab with mirabegron to a drug regimen pegylated liposomal doxorubicin and adebrelimab without mirabegron to see which drug regimen works better to treat relapsed ovarian cancer. Participants will: Take drug pegylated liposomal doxorubicin and adebrelimab every 21 days with or without everyday mirabegron Visit the clinic once every 2 months for checkups and tests Keep a diary of their symptoms
Interventions
DRUGPegylated liposomal doxorubicin plus adebrelimab with mirabegron
Participants receive pegylated liposomal doxorubicin at a dose of 20mg/m2 plus adebrelimab at a dose of 20 mg/kg via intravenous (IV) infusion plus on Day 1 of each 21-day cycle orally with daily mirabegron until intolerance or disease progression.
DRUGPegylated liposomal doxorubicin plus adebrelimab
Participants receive pegylated liposomal doxorubicin at a dose of 20mg/m2 plus adebrelimab at a dose of 20 mg/kg via intravenous (IV) infusion plus on Day 1 of each 21-day cycle until intolerance or disease progression.
Sponsors
Obstetrics & Gynecology Hospital of Fudan University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Has provided documented informed consent for the study. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Has histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. * Has received a front line platinum-based regimen (administered via either intravenous or intraperitoneal route) per local standard of care or treatment guideline following the primary or interval debulking surgery with documented disease recurrence (note: Maintenance treatment following the front line treatment is permitted and counted together as part of the front line treatment). * Has a platinum-free interval (PFI) of \< 12 months if the last regimen received is a platinum-based, or a treatment-free interval (TFI) of \< 12 months if the last regimen received is a non-platinum-based. * Has measurable disease at baseline based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. * Has a life expectancy of ≥12 weeks. * Has provided a tumor tissue sample either collected from prior cytoreductive surgery or fresh newly obtained tumor tissue at screening. * Has adequate organ function. * Has not recovered from AEs to ≤ Grade 1 or prior treatment level due to a previously administered agent.
Exclusion criteria
* Has nonepithelial cancers, borderline tumors, mucinous, seromucinous that is predominantly mucinous, malignant Brenner's tumor and undifferentiated carcinoma. * Has received prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated antigen-4 \[CTLA-4\], tumor necrosis factor receptors OX-40 or CD137) or has participated in prior adebrelimab studies. * Has received prior systemic anticancer therapy including radiation therapy or maintenance therapy within 4 weeks before randomization. * Has severe hypersensitivity (≥Grade 3) or uncontrolled hypertension to pegylated liposomal doxorubicin, adebrelimab, mirabegron and any of their excipients. * Has undergone major surgery within 3 weeks before randomization or has complications/sequelae that have not yet recovered. * Has a known additional malignancy that progressed or required active treatment within the last 5 years. * Is pregnant or breastfeeding. * Has a history of allogenic tissue/solid organ transplant. * Has a history of thrombotic disorders, hemorrhage, hemoptysis, or active gastrointestinal bleeding within 6 months before randomization. * Has a history of active autoimmune disease. * Has an active infection requiring systemic therapy. * Has a history of human immunodeficiency virus (HIV) infection. * Has a history of Hepatitis B or C virus infection. * Has a history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study. * Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate (ORR) | Month 6 | Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR). ORR was defined as the percentage of participants who had a Complete Response (Disappearance of all target lesions) or a Partial Response (≥30% decrease in the sum of the longest diameter of target lesions) using RECIST 1.1 based on BICR. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) at 6 Months | Month 6 | PFS was defined as the time from first dose of study treatment to the first documented progressive disease (PD) per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1 PD was defined as ≥20% increase in SOD of target lesions and an absolute SOD increase of ≥5 mm. The appearance of ≥1 new lesion is also PD. PFS at 6 months is defined as the percentage of patient who was progression free at 6 months from the randomization. |
| Overall Survival (OS) at 6 Months | Month 6 | OS at 6 months is defined as the percentage of patients who are alive at 6 months from the randomization. |
| Overall Survival (OS) at 12 Months | Month 12 | OS at 12 months is defined as the percentage of patients who are alive at 12 months from the randomization. |
| Incidence of grade 3-4 Adverse Events (AEs) | up to 1 month after the end of treatment | Incidence of grade 3-4 AEs, according to CTCAE, version 5.0 |
| Progression Free Survival (PFS) at 12 Months | Month 12 | PFS was defined as the time from first dose of study treatment to the first documented progressive disease (PD) per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1 PD was defined as ≥20% increase in SOD of target lesions and an absolute SOD increase of ≥5 mm. The appearance of ≥1 new lesion is also PD. PFS at 12 months is defined as the percentage of patient who was progression free at 12 months from the randomization. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Exploratory outcome: biomarkers testing and efficacy of anti-tumor immunity | Baseline and 6 months from the randomization | Biomarker testing for PD-L1 expression in exploratory analysis. |
Countries
China
Contacts
Primary ContactCao Doctor
Outcome results
None listed